Atlanta

Atlanta, Georgia 49074

1 studies enrolling now · 19 studies all time

What they study most

C. Diff, C. Difficile, CDI, Cirrhosis, Clostridium Difficile Infection, Clostridium Difficile Infection (CDI), Clostridium Difficile Infection Recurrence, Communicable Diseases, Contraception, Endometriosis, Endometriosis Related Pain, FMT

Studies at this site

• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis — Recruiting now
• Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy — Completed
• 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients — Stopped early
• A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD — Completed
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) — Completed
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) — Completed
• Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD — Stopped early
• LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain — Completed
• Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff — Completed
• Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection — Completed
• LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension — Completed
• SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain — Completed
• SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain — Completed
• Bone Mineral Density in Women With Uterine Fibroids or Endometriosis — Completed
• Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension — Completed